Skyrizi (also known by its generic name risankizumab-rzaa) is a biologic medication that was approved by the FDA in April 2019 for the treatment of moderate-to-severe plaque psoriasis in adults. Skyrizi was approved by the FDA in January 2022 for the treatment of active psoriatic arthritis (PsA) in adults.
Skyrizi was approved by the FDA in June 2026 for the treatment of moderate to severe psoriasis in children (6 years of age and older) who are candidates for systemic therapy or phototherapy or with active psoriatic arthritis. Weight based dosing is available for patients 6 years of age and older who weigh less than 40kg.
For both plaque psoriasis and PsA, Skyrizi is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 12 weeks afterwards.
To learn more, please visit the Skyrizi website.
